Inhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials
Canadian Journal of Respiratory Therapy · 01.08.2023 · 59
DOI: 10.29390/001c.84260 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Canadian Journal of Respiratory Therapy, online erschienen am 01.08.2023. Verfasst von Yasra Badi und 8 weiteren Autor:innen. Beteiligte Einrichtung: All Saints University School of Medicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
More than six million people died due to COVID-19, and 10-15% of infected individuals suffer from post-covid syndrome. Corticosteroids are widely used in the management of severe COVID-19 and post-acute COVID-19 symptoms. This study synthesizes current evidence of the effectiveness of inhaled corticosteroids (ICS) on mortality, hospital length-of-stay (LOS), and improvement of smell scores in patients with COVID-19.
Methods
We searched Embase, Web of Science, PubMed, Cochrane Library, and Scopus until Aug 2022. The Cochrane risk of bias tool was used to assess the quality of studies. We evaluated the effectiveness of ICS in COVID-19 patients through measures of mortality, LOS, alleviation of post-acute COVID-19 symptoms, time to sustained self-reported cure, and sense of smell (visual analog scale (VAS)).
Results
Ten studies were included in the meta-analysis. Our study showed a significant decrease in the LOS in ICS patients over placebo (MD = -1.52, 95% CI [-2.77 to -0.28], p-value = 0.02). Patients treated with intranasal corticosteroids (INC) showed a significant improvement in VAS smell scores from week three to week four (MD =1.52, 95% CI [0.27 to 2.78], p-value = 0.02), and alleviation of COVID-related symptoms after 14 days (RR = 1.17, 95% CI [1.09 to 1.26], p-value < 0.0001). No significant differences were detected in mortality (RR= 0.69, 95% CI [0.36 to 1.35], p-value = 0.28) and time to sustained self-reported cure (MD = -1.28, 95% CI [-6.77 to 4.20], p-value = 0.65).
Conclusion
We concluded that the use of ICS decreased patient LOS and improved COVID-19-related symptoms. INC may have a role in improving the smell score. Therefore, using INC and ICS for two weeks or more may prove beneficial. Current data do not demonstrate an effect on mortality or time to sustained self-reported cure. However, the evidence is inconclusive, and more studies are needed for more precise data.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- All Saints University School of Medicine.
- Joan C. Edwards School of Medicine Marshall University.
- Department of Pharmacotherapy, College of Pharmacy University of Utah.
- Faculty Of Medicine University of Bahri.
- Faculty of Medicine Banha University.
- Faculty of Medicine Minia University.
ORCID-Profile: Yasra Badi, Mohamed Hammad, Abdelrahman G Tawfik, Mona Muhe Eldeen Eshag, Mahmoud M Elhady, Khaled Mohamed Ragab, Anas Zakarya Nourelden, Mohamed Hesham Gamal, Ahmed Hashem Fathallah
Zitieren
APA
Badi, Y., Hammad, M., Tawfik, A. G., Eshag, M. M. E., Elhady, M. M., Ragab, K. M., Nourelden, A. Z., Gamal, M. H., & Fathallah, A. H. (2023). Inhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Canadian Journal of Respiratory Therapy, 59. https://doi.org/10.29390/001c.84260
Vancouver
Badi Y, Hammad M, Tawfik AG, Eshag MME, Elhady MM, Ragab KM, et al. Inhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Canadian Journal of Respiratory Therapy. 2023;59. doi:10.29390/001c.84260
BibTeX
@article{Badi2023,
author = {Badi, Yasra and Hammad, Mohamed and Tawfik, Abdelrahman G and Eshag, Mona Muhe Eldeen and Elhady, Mahmoud M and Ragab, Khaled Mohamed and Nourelden, Anas Zakarya and Gamal, Mohamed Hesham and Fathallah, Ahmed Hashem},
title = {Inhaled corticosteroids’ effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials},
journal = {Canadian Journal of Respiratory Therapy},
year = {2023},
volume = {59},
doi = {10.29390/001c.84260}
}
EUVIMED